New scan could spot lymphoma without PET
NCT ID NCT04292626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new radioactive tracer called 99mTc-1-thio-D-glucose in 16 adults with Hodgkin or non-Hodgkin lymphoma. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it went in the body. The goal was to check safety and whether the tracer can highlight tumors, potentially offering a simpler imaging option than PET scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m labeled 1-Thio-D-Glucose (99mTc-1-thio-D-glucose)
What this could lead to
If successful, this could provide a more accessible imaging option for lymphoma, potentially replacing or complementing PET scans.
What could go wrong
This is a very early phase 1 study with only 16 participants. It focuses on safety and imaging feasibility, not treatment. The new tracer may not prove better than existing methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia